Major funding rounds in AI‑driven biotech, synthetic biology and humanoid robotics in 2026
Large capital inflows highlighted AI‑focused biotech, concentrated synthetic‑biology investment and a surge in humanoid‑robotics financing.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Genetic Engineering
Biotech funding remained steady in 2026, with global venture dollars hovering between $36 billion and $40 billion, while AI‑focused biotechs attracted more than $6 billion of that total. The year’s largest biotech round was a $2.1 billion Series B for London‑based Isomorphic Labs, an AI‑first drug‑design company. Delaware‑based Earendil Labs closed a $787 million round in March to develop AI platforms for protein therapeutics, and San Francisco’s Chai Discovery raised $400 million in a Series C at a $3.8 billion valuation for AI‑driven drug discovery. Longevity specialist NewLimit secured a $435 million Series C in June, underscoring the continued appetite for AI‑enabled therapeutic programmes [1].